Published in Headache on October 01, 2008
Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov (2003) 2.72
Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse (2005) 1.90
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry (2005) 1.67
Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol (2010) 1.62
Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry (2009) 1.47
Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One (2008) 1.36
A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov (2006) 1.26
Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol (2009) 1.21
Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol (2006) 1.07
Biomarkers for chronic pain and analgesia. Part 2: how, where, and what to look for using functional imaging. Discov Med (2011) 1.06
Excitatory neurotransmitters in brain regions in interictal migraine patients. Mol Pain (2009) 1.04
Biomarkers for chronic pain and analgesia. Part 1: the need, reality, challenges, and solutions. Discov Med (2011) 1.03
Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovasc Imaging (2012) 1.02
Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery? Expert Opin Drug Discov (2011) 1.01
Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol (2004) 1.00
Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J Biol Chem (2011) 0.97
The synthesis and preclinical evaluation in rhesus monkey of [¹⁸F]MK-6577 and [¹¹C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. Synapse (2011) 0.96
Synthesis, characterization, and monkey PET studies of [¹⁸F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse (2011) 0.96
Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J Nucl Med (2007) 0.95
Orexin receptors as therapeutic drug targets. Prog Brain Res (2012) 0.91
Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology (2011) 0.90
The premonitory phase of migraine--what can we learn from it? Headache (2015) 0.90
Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist. Mol Imaging Biol (2012) 0.90
Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology (2013) 0.89
Gender and age affect NK1 receptors in the human brain - a positron emission tomography study with [18F]SPA-RQ. Int J Neuropsychopharmacol (2006) 0.88
Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia (2007) 0.88
Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse (2009) 0.87
fMRI of pain processing in the brain: a within-animal comparative study of BOLD vs. CBV and noxious electrical vs. noxious mechanical stimulation in rat. Neuroimage (2011) 0.86
Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache (2008) 0.86
Improved characterization of BOLD responses for evoked sensory stimuli. Neuroimage (2009) 0.85
Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy. Drugs Today (Barc) (2004) 0.84
Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos (2003) 0.83
A 'BOLD' experiment in defining the utility of fMRI in drug development. Neuroimage (2008) 0.83
Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. J Pharmacol Exp Ther (2013) 0.83
Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. Neuroimage (2011) 0.83
fMRI investigation of the effect of local and systemic lidocaine on noxious electrical stimulation-induced activation in spinal cord. Pain (2009) 0.81
Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor. Neuroimage (2010) 0.81
Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways. Nat Protoc (2008) 0.81
Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem (2009) 0.80
Optical molecular imaging in drug discovery and clinical development. Expert Opin Drug Discov (2007) 0.79
Qualification of fMRI as a biomarker for pain in anesthetized rats by comparison with behavioral response in conscious rats. Neuroimage (2013) 0.79
Brain imaging in migraine research. Headache (2010) 0.79
BOLD and blood volume-weighted fMRI of rat lumbar spinal cord during non-noxious and noxious electrical hindpaw stimulation. Neuroimage (2007) 0.79
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos (2003) 0.79
Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) (2011) 0.79
In vivo optical imaging of LacZ expression using lacZ transgenic mice. Assay Drug Dev Technol (2009) 0.78
Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol (2012) 0.78
Pain fMRI in rat cervical spinal cord: an echo planar imaging evaluation of sensitivity of BOLD and blood volume-weighted fMRI. Neuroimage (2008) 0.78
A novel 3-dimensional micro-ultrasound approach to automated measurement of carotid arterial plaque volume as a biomarker for experimental atherosclerosis. Atherosclerosis (2008) 0.77
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discov Today (2011) 0.77
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Drug Discov Today (2011) 0.77
The triptans. Expert Rev Neurother (2009) 0.77
PET imaging studies in rhesus monkey with the cannabinoid-1 (CB1) receptor ligand [11C]CB-119. Mol Imaging Biol (2009) 0.77
In vitro characterization of a gamma-secretase radiotracer in mammalian brain. J Neurochem (2005) 0.76
Advances in the pharmacologic treatment of tension-type headache. Curr Pain Headache Rep (2008) 0.75
Current and emerging therapies for migraine prevention and treatment. Handb Clin Neurol (2010) 0.75
The role of neuroimaging in headache. J Neuroimaging (2002) 0.75
Automated one-step radiosynthesis of the CB1 receptor imaging agent [(18) F]MK-9470. J Labelled Comp Radiopharm (2014) 0.75